A year ago, the world was swept up in a wave of excitement about AI, with grand promises that large language models (LLMs) would transform key industries, from manufacturing to life sciences. Now, as some of these initial solutions begin to reach the market, one area we’re all keenly observing is the impact AI is having on scientific discovery.
A critical player in this movement is Dotmatics, a US-based software company that has been building solutions for scientists to improve the speed and efficiency of their R&D processes for many years.
Investment into R&D for life sciences is growing at an unparalleled rate. And yet for APAC pharmaceutical companies in particular, the ROI of their investment has been declining as the time and cost of bringing a new drug to market has spiked, often costing $2-6 billion per approved drug and taking more than a decade.
That’s precisely why APAC companies are turning to Dotmatics and its …